APR 08, 2020 7:30 AM PDT

Keynote Presentation: New Paradigms in moving toward Point-of-Care Cell Therapy Services in the Hospital

Presented at: BioProcessing 2020
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Resident Physician, John Hopkins
    Biography
      Robert Kruse, MD, PhD is a resident physician at Johns Hopkins training in clinical pathology. He received his MD and PhD degrees from Baylor College of Medicine, studying immunotherapy of hepatitis B virus using CAR-T cells. He will pursue a transfusion medicine fellowship at Harvard Medical School.

    Abstract

    Genetically-modified cell therapies are revolutionizing medicine, offering new opportunities to treat cancer patients and potentially many other diseases. The process of producing gene-modified cell therapies, in particular CAR-T cells, derived from patients is very complex, however, restricting widespread use. The current process involves collection of T cells by apheresis, and shipment from the hospital to a centralized manufacturing site, where cells transduced with gene and grown for 2-3 weeks, before returning to the hospital for infusion into the patient. The significant complexity, freeze/thaw cycles, shipments, and delay in getting therapies pose challenges. As an alternative, a point of care cell therapy production within hospitals would obviate the need for shipping and may reduce the time to get therapies to patients. Automated manufacturing machines will be essential in this paradigm, in order to standardize cellular manufacturing across all hospitals and to deliver the same products to patients. A distributed point-of-care paradigm may ultimately provide an avenue to scale cell therapies to more patients and expand into new clinical indications.

    Learning Objectives:

    1. Define the mechanism of cell therapies and their clinical indications

    2. Identify the key bottlenecks in the delivery of cell therapies to patients today

    3. Explain how point of care cell therapy production in hospitals could work


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    JUN 23, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    JUN 09, 2020 3:00 PM CEST
    C.E. CREDITS
    JUN 09, 2020 3:00 PM CEST
    DATE: June 9, 2020 TIME: 6am PT, 9am ET, 3pm CEST The importance of disposable plastic consumables and their overall impact on the experimental workflow of qPCR has been taken into considera...
    Loading Comments...
    Show Resources